Benzinga | Jan 12, 2022 09:05AM EST

Abbott Receives FDA Clearance For New Cardiac Mapping System

ABBOTT PARK, Ill., Jan. 12, 2022 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite(tm) X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S. and across Europe that is designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias. Designed with input from electrophysiologists from around the world, the system creates highly detailed three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate.